{"id":3148,"date":"2026-09-15T08:00:00","date_gmt":"2026-09-15T12:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3148"},"modified":"2026-09-15T19:59:11","modified_gmt":"2026-09-15T23:59:11","slug":"biomarin-ends-voxzogo-development-in-noonan-syndrome","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3148","title":{"rendered":"BioMarin Ends VOXZOGO Development in Noonan Syndrome"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

BioMarin Pharmaceutical<\/p>\n

Event Type<\/strong><\/p>\n

Portfolio Decision (Program Discontinuation)<\/p>\n

Modality<\/strong><\/p>\n

C-Type Natriuretic Peptide Analog<\/p>\n

Asset<\/strong><\/p>\n

VOXZOGO (vosoritide)<\/p>\n

Target<\/strong><\/p>\n

FGFR3 Signaling Pathway<\/p>\n

Disease Area<\/strong><\/p>\n

Noonan Syndrome (discontinued expansion; approved use remains achondroplasia)<\/p>\n

Summary<\/h4>\n

BioMarin discontinued development of VOXZOGO in children with Noonan syndrome after assessing study feasibility and the current treatment landscape. The company explicitly stated that the decision was not related to VOXZOGO safety or efficacy. The action closes a planned expansion into a genetically heterogeneous short-stature population but does not alter the drug’s approved achondroplasia use or establish a negative biological result in Noonan syndrome.<\/p>\n

The decision was disclosed in a Form 8-K dated September 15, 2026. The associated Phase II registry record describes a randomized study of three vosoritide dose regimens in children with inadequate growth during or after growth-hormone treatment, with six-month annualized growth velocity and longer-term safety and final adult height assessments. The registry still displayed \u201cRecruiting\u201d and an August 24, 2026 update when checked, creating a status discrepancy that the later SEC filing resolves.<\/p>\n

BioMarin did not disclose enrollment, sunk cost, termination procedures, participant transition, or whether data collected to date will be presented. The specific feasibility constraint and relative contribution of the treatment landscape were undisclosed. No safety or efficacy conclusion should be inferred from discontinuation.<\/p>\n

Deep Analysis<\/h4>\n

One interpretation is that recruitment, duration, heterogeneity, or competing growth-hormone care made a development-quality study impractical. The company’s stated feasibility and landscape rationale supports that view. A second interpretation is a portfolio-allocation decision in which expected return no longer justified a long pediatric study. Program termination is consistent with resource prioritization, but no financial or strategic rationale was disclosed. Evidence contradicting either strong conclusion is the explicit absence of a safety or efficacy cause and the lack of operational detail.<\/p>\n

Company and Product Background<\/h4>\n

BioMarin develops therapies for genetically defined rare diseases. VOXZOGO is a C-type natriuretic peptide analog that counteracts overactive FGFR3 signaling to promote endochondral bone growth and is approved for children with achondroplasia. Noonan syndrome comprises RAS\/MAPK-pathway disorders frequently associated with short stature, cardiac disease, and variable growth-hormone response; that heterogeneity complicates trial design and risk-benefit assessment.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • The stale trial registry should not be treated as evidence that development continues.<\/li>\n
  • Upgrades if:<\/strong> the registry posts a sponsor withdrawal with enrollment and rationale, BioMarin provides participant-handling and data-disclosure plans, and portfolio guidance quantifies resource reallocation.<\/li>\n
  • Downgrades if:<\/strong> no data emerge or other growth-condition studies face similar feasibility problems.<\/li>\n
  • Falsified if:<\/strong> available clinical observations remain supportive, or discontinuation occurred before interpretable exposure, undermining any negative-efficacy read.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    This is negative for the Noonan expansion and neutral for VOXZOGO’s established efficacy elsewhere. The filed wording narrows what can responsibly be concluded: it is a study-feasibility and treatment-landscape decision, not a disclosed clinical failure.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal strength:<\/strong> 4\/5 \u2014 discontinuation of a named clinical expansion in a pediatric rare disease. Importance:<\/strong> High \u2014 closes a planned indication expansion for an approved rare-disease therapy. Confidence:<\/strong> High on facts, moderate-low on interpretation \u2014 the decision and stated rationale were filed with the SEC, but feasibility details, enrollment, costs, and portfolio allocation are undisclosed.<\/p>\n","protected":false},"excerpt":{"rendered":"

    BioMarin discontinued development of VOXZOGO in children with Noonan syndrome after assessing study feasibility and the current treatment landscape. The company explicitly stated that the decision was not related to VOXZOGO safety or efficacy….<\/p>\n","protected":false},"author":1,"featured_media":3176,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,11,3],"tags":[758,757],"class_list":["post-3148","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-clinical","category-therapeutic-indication","tag-biomarin-pharmaceutical","tag-noonan-syndrome"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3148","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3148"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3148\/revisions"}],"predecessor-version":[{"id":3178,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3148\/revisions\/3178"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3176"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3148"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3148"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3148"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}